Massachusetts Biotech Lost 3,600 Jobs. This Stealth Firm Is Hiring.

RA Capital's Incubator Launches a Stealth Oligonucleotide Delivery Company

RA Capital's Raven incubator has launched a stealth company betting that the next moat in oligonucleotide medicine isn't chemistry but delivery beyond the liver — and it is staffing up in Cambridge even as Massachusetts biopharma sheds jobs for the first time in two decades.

The Massachusetts Biotechnology Council reported in August 2026 that the state's biopharma workforce contracted 3.1% in 2025 to 113,503 jobs, losing roughly 3,600 positions. R&D employment took the steepest hit among major U.S. hubs, down 3.9% or 2,563 jobs. Venture capital rebounded in the first half of 2026 (Massachusetts companies raised $3.45 billion, up 25% year over year) but capital concentrated in fewer, larger bets, and lab vacancy climbed to 31%. Against that contraction, Raven StealthCo, launched and funded by RA Capital's Raven incubator after what the company describes as a "robust incubation and vetting process," is actively hiring a Principal Scientist in Analytical Chemistry, a Director of Oligonucleotide and Conjugation Chemistry reporting to the VP of Delivery, an Associate Scientist in In Vitro Pharmacology and Assay Development, and a Senior Scientist in Protein Engineering and Discovery Biology. The roles reveal a delivery-first platform strategy: conjugation chemistry and in vitro pharmacology are the scarce inputs at this stage, not target discovery.

Since 2018, Raven has operated as RA Capital's company-building platform, creating more than 30 companies, producing five IPOs, and notching two acquisitions: Mariana Oncology, acquired by Novartis in May 2024, and Aliada Therapeutics, acquired by AbbVie in October 2024. The incubator blends RA Capital's research engine, TechAtlas, which maps more than 130 disease areas and 30 planetary health territories across 5,000-plus company meetings annually, with hands-on formation, capital, and infrastructure. Raven StealthCo sits in Cambridge, led by an experienced chief executive whose name remains undisclosed. It describes itself as a well-funded, discovery-stage biotechnology focused on next-generation oligo-based modalities targeting tissues beyond the liver, muscle, and kidney, therapeutic areas that represent multi-billion-dollar markets growing with an aging population. The disease focus offers strong translatability from animal models to humans, a potentially rapid path to clinic, and "pipeline-in-a-drug" potential: a single gene or protein with meaningful biological effects across multiple disease areas, backed by strong genetic evidence but historically resistant to small-molecule and biologic approaches.

The Battleground Beyond the Liver

Liver delivery is a solved problem. The 2014 discovery that GalNAc conjugates ferry siRNA into hepatocytes (combined with lipid nanoparticle formulations like the one behind Onpattro) gave the field a reliable, scalable route to the liver. Every siRNA drug approved since has exploited that door: Alnylam's Onpattro, Givlaari, Oxlumo, Leqvio (commercialized by Novartis), Amvuttra, and Qfitlia (with Sanofi); Novo Nordisk's Rivfloza. Alnylam's 2025 preliminary net product revenues hit $3B, up 81% year over year, driven almost entirely by transthyretin programs that silence TTR in the liver. The company guides for $4.9–5.3B in 2026 combined revenue. The hepatocyte is no longer the frontier; it is the cash engine.

The frontier is everything else. William Blair analyst Myles Minter told BioSpace in June 2025: "Where we're starting to see innovation, and it still is early stage, although it looks very promising, is trying to deliver to new tissues." Eli Lilly's Andrew Adams, who runs the Lilly Institute for Genetic Medicines, called GalNAc a "unicorn" for its specificity and safety, then added: "We have a lot of work to do to open up si[RNA] beyond the hepatocyte, but... probably once we crack it is going to be similar to when Alnylam and others initially cracked GalNAc, and you'll just sort of walk your way down the list of indications in the new tissue that you open up."

Big Pharma is paying to skip the line. In October 2025, Novartis agreed to acquire Avidity Biosciences at a 100% premium specifically for its Antibody Oligonucleotide Conjugate (AOC) platform that delivers RNA to muscle. The deal closed in 2026; Avidity now operates as a Novartis subsidiary. Three late-stage AOC programs came with it, targeting genetic neuromuscular diseases. Months earlier, Boehringer Ingelheim committed potentially >$2B to Suzhou Ribo Life Science and its Swedish unit Ribocure for siRNA-based MASH treatments. GSK put down $1.2B for Boston Pharmaceuticals' efimosfermin alfa, an FGF21 analog intended to pair with an siRNA drug for the same indication. These are not platform bets on chemistry alone; they are bets on delivery as the moat.

Technical approaches are diverging by tissue. Alnylam's extrahepatic push centers on a C16 lipophilic modification (2-O-hexadecyl attached to siRNA) which in preclinical models achieved knockdown in the central nervous system, eye, and lung with suppression lasting three months and reducing an amyloid-beta isoform in an Alzheimer's mouse model. The company initiated a Phase 1 trial for mivelsiran (CAA and Alzheimer's) and plans a Phase 2 in Alzheimer's in that window. Arrowhead Pharmaceuticals showed mouse data on two siRNA candidates for adipose tissue: one targeting INHBE in hepatocytes, the other ALK7 in adipocytes, with early clinical studies underway. A third Arrowhead candidate, ARO-RAGE, delivered to lung tissue and cut target protein serum levels up to 88% in asthma patients in a Phase 1/2 interim readout.

No single chemistry will unlock every tissue. The market math reflects that reality: the global oligonucleotide therapeutics market, valued at $7.2B in 2025, is projected to reach $29.6B by 2033 at a 19.4% CAGR. The growth assumption is explicit: the next wave of value comes from tissues the current toolkit cannot reach. Alnylam's own 2030 strategy targets expansion to 10 tissue types and more than 40 clinical programs, with roughly 30% of revenues reinvested in R&D including external innovation. The bottleneck is no longer oligonucleotide chemistry. It is the delivery vehicle, tissue by tissue.

What Early Hires Trade for Infrastructure

Traditional venture-backed biotechs launch with a term sheet and a prayer. The founding team (often a scientist and a business lead) spends months negotiating leases, setting up payroll, filing IND-enabling study contracts, and cold-calling CROs. Raven operates differently. Its 20-plus venture partners, entrepreneurs-in-residence, and advisors don't just write checks; they supply corporate infrastructure (formation, governance, finance, legal, HR, operational systems) before the first scientist walks through the door.

That infrastructure includes Blackbird, Raven's internal scientific and clinical development engine. Blackbird handles study design, clinical trial recruitment, regulatory strategy, CMC support, CRO management, and data analysis. For a discovery-stage hire at Raven StealthCo, this means the in vitro pharmacology engine they're being asked to build (target ID, pathway validation, oligonucleotide profiling, mechanism-of-action work) plugs into a clinical translation apparatus that already exists. The "platform risk" that sinks many Series A companies — can we actually run a trial? — is substantially de-risked by the time a Raven company hires its first associate scientist.

The difference shows up in the hiring itself. When Raven identifies an unmet need with no investable company addressing it (the "Identify unmet needs" mode), it can license technology from academia, recruit a founding team, and build the company from scratch. The hiring plan isn't improvised; it's derived from a mapped competitive landscape. For the pharmacology and conjugation chemistry roles at Raven StealthCo, the mandate is specific: build the delivery platform for tissues beyond liver, muscle, and kidney.

Raven's own recent hiring signals the platform's maturity. In late 2026, the incubator added venture partners Alison Tisdale, Camille Landis, and Kleem Chaudhary; entrepreneur-in-residence Charlotte McDonagh; senior scientist Aarya Venkat in protein design and modeling; and operational leaders Kinsey Medlin in patient recruitment and Tammy Toole in regulatory strategy. These aren't portfolio company hires — they're Raven hires, expanding the capacity to spin up the next StealthCo. The platform currently manages $12.6 billion in assets (March 2025) with 130 employees at the management company level, while the Raven incubator team itself runs lean at 11-50 people.

For an early hire, the trade-off is clear. You surrender the chaos (and the equity upside) of a true garage startup. In exchange, you get role clarity: the lab space exists, the CRO relationships are negotiated, the regulatory strategy is drafted, and the capital strategy extends beyond the next raise. The risk shifts from "can we build a company?" to "can this chemistry reach muscle, CNS, lung, and immune cells?" That's a scientific bet, not an operational one. Raven's track record (Mariana Oncology, Aliada Therapeutics, Solstice Oncology's $225 million Series A, Serapha Bio's advancing pipeline) suggests the model works for operators who prefer to bet on science over company-building.

Reading the Hiring Plan

The job postings tell a clearer story than any press release. Raven StealthCo is hiring a Senior Scientist for Protein Engineering and Discovery Biology and an Associate Scientist for that role. Together, these roles map a platform built around antibody-oligonucleotide conjugates — not small-molecule ligands, not lipid nanoparticles alone — as the vehicle to reach tissues the liver already surrenders to.

The protein engineering role is the giveaway. The description asks for hands-on expertise with binding assays (ELISA, SPR, BLI, flow cytometry), cell-based internalization assays to assess antibody trafficking and receptor-mediated uptake, and functional assays for receptor agonism or antagonism. That is the toolkit of a team engineering bispecific antibodies: one arm binds a surface receptor on the target tissue, the other carries the oligonucleotide payload. The requirement to "perform and interpret antibody biophysical characterization studies (e.g., thermal stability, aggregation propensity, binding kinetics) to support developability assessment" signals they are past early discovery and into lead optimization, selecting candidates that survive manufacturing and dosing regimens. The mandate to "bring in new methods, technologies, and vendors where existing approaches fall short, and operationalize methods once established: robust, documented, transferable assays with defined controls, acceptance criteria, and performance tracking" reads like a group building the assay infrastructure that will later support IND-enabling work.

The in vitro pharmacology role completes the loop. That posting seeks someone to "build and run the in vitro pharmacology engine (target ID and pathway validation, oligonucleotide profiling, and mechanism-of-action work) and to execute the ex vivo analyses." Target ID and pathway validation means they are still nominating which receptors to chase: which tissues, which cell types, which disease contexts. Oligonucleotide profiling means they are testing chemistry variants (backbone modifications, sugar modifications, conjugate linkers) against those targets in parallel. Mechanism-of-action work means they need to prove the conjugate actually releases the oligo inside the cell and engages the intended RNA target. Ex vivo analyses means they are already harvesting tissues from animal models to measure distribution, uptake, and pharmacodynamics outside the liver.

Salary bands confirm the stage. The protein engineering role lists $110K–$160K base, competitive for a Cambridge discovery shop, but not a late-stage clinical operation. The posting date (September 18, 2026) and the line "Given our recent funding and commitment to building a first-in-class platform" place this build-out squarely after a Series A or equivalent incubator capitalization. The company describes itself as "in the discovery stage and will invest heavily in our emerging platform for oligonucleotide delivery."

What this means for the people who take these roles: you are not joining a program team advancing a single asset. You are joining a platform team that must solve delivery first, then hang indications on it. Both will write SOPs, qualify equipment, and train the next hires because the lab is still being built. The "pipeline-in-a-drug" language in the job description — that phrase — is the commercial argument for the platform: one delivery vehicle, many shots on goal.

The technical bet is visible in the assay stack. SPR and BLI for kinetics. Flow cytometry for internalization. Cell-based functional assays for receptor modulation. This is not a team screening peptide libraries; it is a team engineering antibody conjugates with defined biophysical properties. The omission of LNP formulation scientists from the current postings is notable; either that capability sits elsewhere in the Raven network, or the platform has already chosen conjugates as the primary modality. Either way, the hiring plan says the bottleneck is not chemistry synthesis but biological validation: does the conjugate reach the right cell, enter it, release the payload, and modulate the target without toxicity.

For operators, the signal is clarity. The roles are defined by assay types and deliverables, not vague "platform contributions." For engineers, the signal is constraint: you will work at the intersection of protein engineering and oligonucleotide pharmacology, where the physics of a 150 kDa antibody meets the chemistry of a 7 kDa oligo. That intersection is where the extrahepatic delivery war will be won or lost. Raven StealthCo is staffing it.

Working in frontier tech? Zero G Talent tracks the openings: see every open Raven Space role, browse frontier tech jobs, the companies hiring, and the people building the field.